Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Tongguang Shanliang Health Technology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. Such a concentrated profile suggests that the company is currently pursuing a specific set of claims or a single patent application within the pharmaceutical space.
The busiest examiner, VIGIL, TORIANA NICHOLE, is handling 1 busiest examiner pending action. Because this 1 busiest examiner pending action is the only one currently pending for the company, the entire prosecution strategy is focused on this single interaction. The lack of multiple examiners or art units means there is no diversity in the feedback the company is receiving from the patent office.
With 1 pending office action and 1 distinct examiner, the administrative burden of this portfolio is low. The focus on 1 distinct art unit further emphasizes the specialized nature of the technology being patented. VIGIL, TORIANA NICHOLE'S role as the sole examiner for the 1 pending action makes her the primary point of contact for the company's current intellectual property efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18590939 | COMPOSITION HAVING EFFECTS OF PROTECTING EYES AND IMPROVING EYESIGHT AND USE THEREOF IN FIELD OF PREPARING FOOD OR MEDICINE | VIGIL, TORIANA NICHOLE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18590939 | COMPOSITION HAVING EFFECTS OF PROTECTING EYES AND IMPROVING EYESIGHT AND USE THEREOF IN FIELD OF PREPARING FOOD OR MEDICINE | VIGIL, TORIANA NICHOLE | 1626 | §103 | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Tongguang Shanliang Health Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Toriana Nichole Vigil has the most, with 1 of Shanghai Tongguang Shanliang Health Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.